HS-25
Asset
Cholesterol absorption inhibitor targeting NPC1L1
- Stage
- Phase 3
- Modality
- Small molecule
- Target
- Lipid and ceramide metabolism
- 2
- Indications
- 557
- Trials
- 1
- Developer
Indications
2Hypercholesterolemia in coronaory heart disease
Phase 3, Completed, NCT03433196, clinicaltrials.gov, 7 Oct 2026
Primary hypercholesterolemia
Phase 3, Unknown, NCT03464682, clinicaltrials.gov, 7 Oct 2026
In the full profile
- Targets and what it contains3
- Owner and partners1
- Trials557
- Evidence for its targets3
- Competitors12
- Signals11
Every asset’s record: target, stage, trials and the evidence behind it.